What we do

Myconostica Ltd develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life-threatening invasive fungal infections.

Traditional methods for the detection of fungal pathogens, such as culture and microscopy, are well-documented as being relatively insensitive and slow. Myconostica uses advances in molecular techniques, such as Real-Time PCR, to develop a range of assays for the rapid, accurate and sensitive detection of fungi such as Aspergillus spp., Pneumocystis jirovecii and Candida spp.

Evidence shows that an early diagnosis of invasive fungal infection significantly improves the chance of survival. Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease reduces the patient’s exposure to inappropriate drug treatments, improves patient outcomes and reduces the hospitalisation and treatment costs associated with invasive fungal disease.

We are a spin-out company of the University of Manchester, and a Partner Company of Amphion Innovations plc. (Amphion, AIM: AMP, develops and operates companies in the life sciences and technology sectors).


To receive the latest product information, subscribe to our newsletter here.